Glycosylated Peptide Market by Product Type (Monoclonal Antibodies [MABs], Erythropoietin [EPO], and others) and by Application (Oncology, Blood Disorder, and others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

Get 20% Free Customization In This Report

Pharmaceuticals	LI_183471	Pages: NA	May 2019 \| 920 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Glycosylated peptide are used as a mediators of key biological function with unique intrinsic properties with potential to treat variety of diseases. Glycosylation of peptide drugs benefits with key features such as increased half-life, provides extended dosing duration, better solubility, and improved response to the therapy. The key factors that drive the market growth are the benefits of these peptides that show high biological activity, availability of innovative peptides in the market, and rise in incidence of chronic diseases worldwide. However, the intrinsic complexity for manufacturing and high cost of the active pharmaceutical ingredient (API) restricts the market growth. Nevertheless, ongoing R&D activities and increase in investment by the pharmaceutical companies offer ample opportunities to the market growth.

This global market is segmented on the basis of product type such as monoclonal antibodies (MABs), erythropoietin (EPO), and others. Based on application, the market is divided into oncology, blood disorder, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the market include Sandoz International GmbH, Pfizer Inc. Roche Ltd, Teva Pharmaceuticals Industries Ltd, Celltrion Inc., Biocon Ltd., Dr.Reddys Laboratories Ltd, Medtronic plc, Cipla Inc, and Bachem Americas, Inc.

Key Benefits

The study provides an in-depth analysis of the global glycosylated peptide market along with current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market by product assists to understand the various forms of autoimmune disease diagnostic available.
Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

Glycosylated Peptide Market Key Segments:

By Product Type

Monoclonal Antibodies (MABs)
Erythropoietin (EPO)
Others

By Application

Oncology
Blood Disorder
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Argentina
- South Africa
- Rest of LAMEA

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 GLOBAL GLYCOSYLATED PEPTIDE MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MONOCLONAL ANTIBODIES (MABS)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. ERYTHROPOIETIN (EPO)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. OTHERS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 GLOBAL GLYCOSYLATED PEPTIDE MARKET, BY APPLICATION TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ONCOLOGY

5.2.1. Market size and forecast

5.3. BLOOD DISORDER

5.3.1. Market size and forecast

5.4. OTHERS

5.4.1. Market size and forecast

Chapter: 6 GLOBAL GLYCOSYLATED PEPTIDE MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Glycosylated Peptide Market by Product Type
6.2.5. North America Glycosylated Peptide Market by Application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Glycosylated Peptide Market by Product Type
6.3.5. Europe Glycosylated Peptide Market by Application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Glycosylated Peptide Market by Product Type
6.4.5. Asia-Pacific Glycosylated Peptide Market by Application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Argentina market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Glycosylated Peptide Market by Product Type
6.4.5. Asia-Pacific Glycosylated Peptide Market by Application

Chapter: 7 COMPANY PROFILES

7.1. SANDOZ INTERNATIONAL GMBH

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.3. PFIZER INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.3. ROCHE LTD

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. TEVA PHARMACEUTICALS INDUSTRIES LTD

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. CELLTRION INC

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. BIOCON LTD.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. DR.REDDY’S LABORATORIES LTD

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MEDTRONIC PLC

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. BACHEM AMERICAS, INC.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. CIPLA INC.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Glycosylated Peptide Market by Product Type (Monoclonal Antibodies [MABs], Erythropoietin [EPO], and others) and by Application (Oncology, Blood Disorder, and others) - Global Opportunity Analysis and Industry Forecast, 2018-2025